Skip to main content

Advertisement

SpringerLink
Log in

A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Patients with metastatic or recurrent esophageal squamous cell carcinoma (ESCC) have a poor prognosis. For decades, the most widely used first-line chemotherapy regimen for these patients has been the combination of 5-fluorouracil + cisplatin (CF). However, prognostic factors of CF as first-line chemotherapy for ESCC have not been clarified.

Methods

A total of 187 patients with metastatic or recurrent esophageal ESCC treated with CF at the National Cancer Center Hospital between January 2001 and December 2012 were enrolled in the study. The CF regimen comprised cisplatin (80 mg/m2) administered on day 1 and 5-fluorouracil (800 mg/m2) administered continuously on days 1–5, every 4 weeks. Multivariate Cox regression analysis was used to determine the potential prognostic factors.

Results

The median age of the patients was 62 (range 34–84) years. Metastasis and recurrence occurred in 116 and 71 of these patients, respectively. The overall response rate was 37.2%, with median progression-free and overall survival times of 4.8 and 10.4 months, respectively. In the multivariate analysis, higher serum C-reactive protein level and lower serum albumin level at the time of CF treatment initiation and number of metastatic sites were identified as independent prognostic factors for survival.

Conclusions

The results of this study corroborate previous findings on the efficacy of CF and will aid physicians in clinical decision-making and individual patient risk stratification, as well as in the further development of chemotherapy regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. International Agency for Research on Cancer (IARC) GLOBOCAN 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

  2. Tachimori Y, Ozawa S, Numasaki H et al (2016) Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus 13:110–137

    Article  PubMed  PubMed Central  Google Scholar 

  3. Coonley CJ, Bains M, Hilaris B et al (1984) Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report. Cancer 54(11):2351–2355

    Article  PubMed  CAS  Google Scholar 

  4. Marcullo E, Alba E, de Segura GG (1988) Cisplatin and intravenous continuos infusion of bleomycin in advanced and metastatic esophageal cancer. Eur J Cancer Clin Oncol 24(4):633–635

    Article  Google Scholar 

  5. Iizuka T, Kakegawa T, Ida H et al (1991) Phase II evaluation of combined cisplatin and vindecine in advanced squamous cell carcinoma of the esophagus. Jpn J Clin Oncol. 21(3):176–179

    PubMed  CAS  Google Scholar 

  6. Dinwoodie WR, Bartolucci AA, Lyman GH et al (1986) Phase II evaluation of cisplatin, bleomycine in advanced squamous cell carcinoma of the esophagus. Cancer Treat Rep 70(2):267–270

    PubMed  CAS  Google Scholar 

  7. Kok TC, Van der Gaast A, Dees J et al (1996) Cisplatin and etoposide in oesophageal cancer; a phase II study. Rotterdam Oesophageal Tumor Study Group. Br J Cancer 74(6):980–984

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Bleiberg H, Conroy T, Paillot B et al (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33(8):1216–1220

    Article  PubMed  CAS  Google Scholar 

  9. Iizuka T, Kakegawa T, Ide H et al (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: Japan Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172–176

    PubMed  CAS  Google Scholar 

  10. Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group Trial (JCOG9407). Jpn J Clin Oncol 31(9):419–423

    Article  PubMed  CAS  Google Scholar 

  11. Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68–74

    Article  PubMed  Google Scholar 

  12. Muro K, Hmaguchi T, Ohtsu A et al (2004) A phase II study of single-agent in phase with metastatic esophageal cancer. Ann Oncol 15(6):955–959

    Article  PubMed  CAS  Google Scholar 

  13. Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272

    Article  PubMed  CAS  Google Scholar 

  14. Shirakawa T, Kato K, Nagashima K et al (2014) A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine-and platinum-based chemotherapy. Cancer Chemother Pharmacol 74(6):1207–1215

    Article  PubMed  CAS  Google Scholar 

  15. Tamura S, Imano M, Takiuchi H et al (2012) Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 32:1403–1408

    PubMed  CAS  Google Scholar 

  16. Osaka Y, Shinohara M, Hoshino S et al (2011) Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31:633–638

    PubMed  CAS  Google Scholar 

  17. Hironaka S, Tsubosa Y, Mizusawa J et al (2014) Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci 105(9):1189–1195

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Kato K, Muro K, Ando A et al (2014) A phase II of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus (JCOG9905-DI). Esophagus 11:183–188

    Article  CAS  Google Scholar 

  19. Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Nozoe T, Ninomiya M, Maeda T et al (2010) Prognostic nutritional index: a tool to predict the biological aggressivenesss of gastric carcinoma. Surg Today 40:440–443

    Article  PubMed  Google Scholar 

  21. Maeda K, Shibutani M, Otani H et al (2014) Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. World J Surg 38:1217–1222

    Article  PubMed  Google Scholar 

  22. Kanda M, Fujii T, Kodera Y et al (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268–274

    Article  PubMed  CAS  Google Scholar 

  23. Masaichi O, Naoshi K, Go M et al (2015) Glasgow prognostic score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res 35:4897–4902

    Google Scholar 

  24. Okuno T, Wakabayashi M, Kato K et al (2017) Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). Int J Clin Oncol 22(6):1042–1049

Download references

Acknowledgements

We gratefully thank Emiko Usami for data acquisition and Kengo Nagashima PhD for for statistical analysis.

Author information

Authors and Affiliations

  1. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Shuji Hiramoto, Ken Kato, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Satoru Iwasa, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada & Narikazu Boku

  2. Department of Clinical Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital, Nishikyo-ku, Kyoto, Japan

    Shuji Hiramoto

Authors
  1. Shuji Hiramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hirokazu Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natsuko Okita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsuo Takashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoru Iwasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsuya Hamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasuhide Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuhiro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Narikazu Boku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Kato.

Ethics declarations

Conflict of interest

The authors state that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiramoto, S., Kato, K., Shoji, H. et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol 23, 466–472 (2018). https://doi.org/10.1007/s10147-018-1239-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1239-x

Keywords

Search

Navigation